Clinical trial NCT00177281: Safety Study of S-CKD602 in Patients With Advanced Malignancies
Official title: A Phase I Study to Evaluate the Safety and Pharmacokinetics of S-CKD602 in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: ALZA
First posted: 2005-09-15
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to evaluate a new anti-cancer drug called S CKD602, developed by ALZA Corporation. The drug is investigational and not approved by the Food and Drug administration (FDA). The side effects (the way the drug acts in your body) and the effect it has on your disease will be studied.

Detailed description: The main purposes of this study are:

To determine the maximum tolerated dose (highest dose that can safely be given to subjects) of S CKD602 when given every three weeks.

To determine the incidence and severity of toxicity (side-effects) of S CKD602 when given every three weeks.

To determine a subject's body handles the drug (pharmacokinetics) following administration of S CKD602.

In addition to the above, we would also like to analyze how the genes (material inside each cell that is responsible for cell functioning and appearance) found in a subject's blood affect how the study drug S-CKD602 is broken down in a subject's body. This process is referred to as "metabolic genotyping analyses". This evaluation is performed using a blood sample and is optional.

Eligibility criteria: Inclusion Criteria:

Male or female subjects with an age \> 18 years Histologically or cytologically proven malignancy, unresponsive to curative surgery, radiotherapy, conventional chemotherapy or for which no conventional therapy exists. (Measurable or evaluable disease is desirable, but not required) Note: This study is restricted to patients with advanced solid tumors, subjects with hematological malignancies are excluded (including lymphoma and leukemia) ECOG Performance Status 0- 2 Adequate bone marrow function, without the support of cytokines and/or Epoetin Alpha within 5 days prior to dosing: Absolute neutrophil count (ANC) \>1,500/mm3, platelet count \> 100,000/mm3, Hgb \> 9.0 g/dL. Adequate liver function: total bilirubin level \< 2.0 mg/dL, ALT and AST \< 2.0 x institutional upper limit of normal in the absence of liver metastasis, or \< 4.0 x institutional upper limit of normal in the presence of liver metastasis.

Adequate renal function: serum creatinine \< 1.5 mg/dL. At least 3 weeks since prior chemotherapy or cancer surgery (6 weeks for nitrosourea or mitomycin C).

Normal cardiac function with no history of uncontrolled heart disease. Women subjects (if of child bearing potential and sexually active) and male subjects (if sexually active with a partner of child bearing potential) must use medically acceptable methods of birth control prior to study entry and for the duration of the study. Medically acceptable methods of contraception that may be used by the subject and/or his/her partner include abstinence, birth control pills or patches, diaphragm and spermicide, IUD, condom and vaginal spermicide, surgical sterilization, post menopausal, vasectomy, and progestin implant or injection.

Written informed consent.

Exclusion Criteria:

Subject is pregnant or is breast feeding. Subject's life expectancy is less than 3 months. Subject exhibits confusion, disorientation, or has a history of major Psychiatric illness, which may potentially impair subject's understanding of the informed consent.

Subject has signs and symptoms of acute infection requiring systemic therapy. Subject has used another investigational agent within 30 days of dosing with S CKD602.

Subjects with known allergic reactions to camptothecin analogs, dextran sulfate or other components of S-CKD602 Symptomatic or uncontrolled brain leptomeningeal metastasis. CT scans are not required unless there is clinical suspicion of central nervous disease.

Not recovered from reversible toxicity of prior therapy. Subjects with known brain metastases because of their poor prognosis because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

Concurrent radiation therapy or radiation within 3 weeks of starting treatment with S-CKD602.

Concurrent anti-neoplastic agents.

Primary outcomes:
measure: To determine the maximum tolerated dose of S CKD602 when given every three weeks.
measure: To determine the incidence and severity of toxicity of S CKD602 when given every three weeks.
Secondary outcomes:
measure: To determine the pharmacokinetics of CKD 602 following administration of S CKD602.
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Ramesh K Ramanathan, MD
role: PRINCIPAL_INVESTIGATOR
References: